Austin Collier

Austin Collier is an associate in the litigation department at Goodwin. He started at the firm in 2021. Austin concentrates his legal practice in representing a wide variety of tech and financial companies in complex litigation, privacy, and investigatory matters.

• In re: HIV Antitrust Litigation, C.A. No. 19-02573-EMC (N.D. Cal.); Member of trial team defending Teva Pharmaceuticals against reverse-payment antitrust claims challenging prior settlement of Hatch Waxman patent litigation brought by Gilead regarding Teva’s generic versions of Viread® (tenofovir), Truvada® (tenofovir/emtricitabine), and Atripla® (tenofovir/emtricitabine/efavirenz). Secured a total defense verdict of no anticompetitive reverse payment and no market power, following six-week N.D. Cal. jury trial seeking damages of $3.8 billion (before mandatory trebling) from defendants Teva and Gilead Sciences
• Represented a private equity firm focused on the healthcare services sector and a portfolio company in a post-closing lawsuit pending in Delaware state court concerning purported inaccuracies in the representations and warranties in the purchase agreement regarding the company’s financial statements
• Guided clients in a wide range of cybersecurity and privacy incidents to protect clients from malware and cyber criminals as part of my work with Goodwin’s Data Privacy and Cybersecurity group
• Represented numerous class-action defendants against privacy based allegations under statutes including BIPA and TCPA  
  
• Guided clients in a wide range of cybersecurity and privacy incidents to protect clients from malware and cyber criminals as part of my work with Goodwin’s Data Privacy and Cybersecurity group
• Advised on multiple post-transactional disputes for tech and life science clients

Prior to joining Goodwin in New York, Austin was a web data analyst specializing in consumer behavior in Boston, Massachusetts.